Noninferiority established through high treatment success, low adverse event rates
Findings presented at ESC Congress 2023 and simultaneously published in The New England Journal of Medicine
https://www.marketscreener.com/quote/stock/BOSTON-SCIENTIFIC-CORPORA-11935/news/ADVENT-Study-of-the-FARAPULSE-trade-Pulsed-Field-Ablation-System-Meets-Primary-Efficacy-and-Safety-44707946/
Note: Only a member of this blog may post a comment.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.